Finally, the eye health market itself is of several different kinds. One of the largest of these is the broader eyecare market which was worth $6.6 billion in 2021 according to a research report from Reports and Data. From this, the firm expects the market to grow at a 3.8% CAGR to 2030, and be worth an estimated $42.5 billion by the end of the forecast period. The research firm believes that one of the primary drivers of growth in this market is the growth in screen time for both younger and older adults, especially since computer screens and other products are regularly used for a wide variety of uses including entertainment and work. It shares that the intraocular lens product segment constituted the largest part of the market in 2019, and it will continue to do so by the end of 2030, as it will account for 45.2% of the overall market. The popularity of intraocular lenses is due to the simple fact that they allow people with vision impairments to avoid wearing glasses after their surgeries, and since they can treat a range of eye diseases such as astigmatism, farsightedness, and nearsightedness. Segmenting the region geographically, Reports and Data adds that North America was the world's largest eyecare products market, with a wider prevalence of eye diseases in China driving growth in Asia.
The growth in screen use globally is confirmed when we take a look at the latest earnings call transcript from The Cooper Companies, Inc. (NYSE:COO). In its analyst conference for the first quarter of the fiscal year of 2023, the company's chief executive officer and president Mr. Al White shared:
Studies show that adults are now spending more than seven hours a day on screens, resulting in eye ceiling strain and discomfort. Energys, with its boost technology is the perfect solution to address this digital eye fatigue. And our survey work clearly shows that practitioners and customers are excited to get this technology and a daily offering. All this MyDay activity is exciting, and we remain dedicated to developing and rolling out technologically superior MyDay products for many years to come. Lastly, within the daily segment, Clarity is performing well. Its mass market price point is allowing eye care practitioners to continue utilizing the Clarity franchise as a great way to bring wares into the daily silicone hydrogel space. Moving outside of dailies.
Today, we'll look at some great eyecare stocks in terms of analyst upside. Out of these, some picks are EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), OKYO Pharma Limited (NASDAQ:OKYO), and Kala Pharmaceuticals, Inc. (NASDAQ:KALA).
Our Methodology
We took a broad look at the healthcare sector to narrow down those firms that also offer eyecare products. Then, we researched to determine if their consensus share price target estimates are higher than the current share price. The companies that had the highest share price upside were selected, and out of these ten firms are chosen. These companies are ranked according to their market capitalization, starting from the most valuable company at number ten.
Latest Market Capitalization: $173 billion
Novartis AG (NYSE:NVS) is a Swiss healthcare company headquartered in Basel, Switzerland. The company makes and sells eye drops for problems such as inflammation and swelling in the back of the eye. Apart from this, the firm also makes other drugs such as those that target cancer and heart problems.
By the end of last year's fourth quarter, 22 of the 943 hedge funds polled by Insider Monkey had held a stake in Novartis AG (NYSE:NVS). Out of these, the firm's largest investor is Peter Rathjens, Bruce Clarke, and John Campbell's Arrowstreet Capital which owns 4.1 million shares that are worth $374 million.
Along with OKYO Pharma Limited (NASDAQ:OKYO), EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), and Kala Pharmaceuticals, Inc. (NASDAQ:KALA), Novartis AG (NYSE:NVS) is an eyecare stock with high upside potential.
Latest Market Capitalization: $35.8 billion
Centene Corporation (NYSE:CNC) is a healthcare coverage plan provider. It enables customers to take eye exams and buy eye care products such as glasses, lenses, contacts, and other products. The firm is headquartered in Saint Louis, Missouri.
Insider Monkey took a look at 943 hedge funds for last year's fourth quarter and found out that 58 had invested in Centene Corporation (NYSE:CNC). Out of these, Quentin Koffey's Politan Capital is the firm's largest investor since it owns 13.1 million shares that are worth $1 billion.
Latest Market Capitalization: $33.8 billion
Alcon Inc. (NYSE:ALC) is one of the more well known eye care product providers. The firm is headquartered in Geneva, Switzerland, and it a variety of products such as intraocular lenses, surgical packs, microscopes, visualization systems, and medicines to relieve symptoms of eye diseases such as glaucoma and allergies. Its product portfolio makes it a great eye care stock.
Alcon Inc. (NYSE:ALC)'s shares currently trade around $67, while its average analyst price target is $84. As of December 2022, 26 of the 943 hedge funds polled by Insider Monkey had invested in the company. Alcon Inc. (NYSE:ALC)'s largest shareholder is Nicolai Tangen's Ako Capital which owns 5.6 million shares that are worth $385 million.
Latest Market Capitalization: $17.2 billion
The Cooper Companies, Inc. (NYSE:COO) is an American firm headquartered in San Ramon, California. The firm primarily focuses on making and selling contact lenses for eye problems such as farsightedness, nearsightedness, astigmatism, and other problems.
The Cooper Companies, Inc. (NYSE:COO)'s shares currently trade at around $348, with the average analyst share price target being $372. Insider Monkey's Q4 2022 survey of 943 hedge funds revealed that 37 had held a stake in the firm. The Cooper Companies, Inc. (NYSE:COO)'s largest investor is Parag Vora's HG Vora Capital Management which owns 3.4 million shares that are worth $138 million.
Latest Market Capitalization: $5.6 billion
Bausch + Lomb Corporation (NYSE:BLCO) is another renowned eyecare firm that is known for its products such as contact lenses, eye drops, eye vitamins, and more. The firm is based in Vaughan, Ontario, Canada.
As of December 2022, 27 of the 943 hedge funds surveyed by Insider Monkey had invested in Bausch + Lomb Corporation (NYSE:BLCO). The firm has an average analyst share price target of $28.7, higher than its current share price.
Along with, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), OKYO Pharma Limited (NASDAQ:OKYO), and Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Bausch + Lomb Corporation (NYSE:BLCO) is an eyecare stock with a significant share price upside.
Click to continue reading and see 5 Eyecare Stocks With Upside Potential.
Suggested Articles:
Disclosure: None. The author received no additional compensation for this piece except for what is typically made by Insider Monkey. 10 Eyecare Stocks With Upside Potential is originally published on Insider Monkey.